NAD+ Injections Dosage Chart: What Trials Tested and What No Study Sets
Clinic dosage charts look precise. The published research does not set an injection dose, and here is what it does show.
Words by the editors ·
There is no validated dosage chart for NAD+ injections. No NAD+ injection has an FDA-approved label with a dose, and the most recent review of intravenous NAD+ concluded that optimal dosing, along with efficacy, durability and long-term safety, cannot currently be established.1 Any chart that lists milligrams by week is a vendor's protocol, not a published standard. This page sets out what the research does give us: the doses used in human trials of NAD+ precursors, where they came from, and what to ask a prescriber.
In brief
- A 2026 review of intravenous NAD+ concluded that optimal dosing cannot currently be established.1
- Trials with verified doses tested oral precursors: 250 mg per day of NMN and 2,000 mg per day of nicotinamide riboside.234
- Compounded NAD+ injections are not FDA-approved and the FDA does not verify their safety, effectiveness or quality.5
- Reported effects include nausea, cramping, flushing and chest discomfort for intravenous NAD+; long-term safety data are lacking.1
Is there an official NAD+ injection dose?
No. A compounded drug is made by a pharmacy for an individual patient, and the FDA says compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before they are marketed.5 Adults who buy NAD+ injections online therefore receive a compounded product with no approved label to set the dose, the schedule or the maximum.
The 2026 narrative review of intravenous NAD+ and NAD+ precursors searched the literature from 2018 to March 2026. It found the human evidence "sparse," made up mainly of small uncontrolled studies, observational reports and case reports, and said the evidence is insufficient to support routine clinical or wellness use.1 A lack of controlled injection trials is the reason no reliable chart exists.
What doses have human trials actually tested?
The randomized trials we could verify tested oral precursors, not injections. They are useful for showing the scale researchers used, but a swallowed dose and an injected dose are different exposures, and these numbers must not be read as injection doses.
| Trial | Product and dose | Who and how long | What it found |
|---|---|---|---|
| Igarashi 20222 | Oral NMN, 250 mg per day | Healthy older men, 6 or 12 weeks, placebo-controlled | Blood NAD+ rose; gait speed and grip changes were only nominally significant; no body composition effect |
| Dollerup 20183 | Oral NR, 1,000 mg twice daily (2,000 mg per day) | Obese, insulin-resistant men aged 40 to 70, 12 weeks, placebo-controlled | Appeared safe; no improvement in insulin sensitivity, energy expenditure or body composition |
| Wu 20254 | Oral NR, 2,000 mg per day | 58 adults with long-COVID, 24 weeks, placebo-controlled; NR maker part-funded | NAD+ rose about 2.6- to 3.1-fold; no significant fatigue difference from placebo |
These doses differ by a factor of eight, and the trials measured different outcomes in different people. Even among oral precursors there is no single "right" dose; researchers chose amounts to test safety and blood NAD+ levels. The systematic review of 10 randomized trials (489 participants) of NAD+ and NADH products ended by saying future studies are needed on benefits in specific conditions and on the doses to give.6
What do injection or infusion protocols look like?
We did not find a controlled trial that sets out an injection schedule for healthy adults, so we do not list one. The intravenous literature is small series and case reports, and the authors of the 2026 review say its heterogeneous methods and short follow-up prevent firm conclusions on dose.1 A second 2026 critical review of intravenous "longevity" infusions that include NAD+ described few placebo-controlled trials and conflicting results, and said such therapy should be regarded as experimental.7 Neither source supports a particular number of milligrams, a frequency or a course length.
That matters when a clinic's chart looks precise. Precision on a handout is not evidence behind it. If a chart is offered, the useful question is which study the dose came from, in whom, and by which route.
What side effects should shape dosing?
The intravenous review lists nausea, cramping, flushing and chest discomfort as reported effects and says long-term safety data are lacking.1 In the oral-product review every included trial reported some side effects, most often muscle pain, nervous disorders, fatigue, sleep disturbance and headache, none judged a serious risk to participants.6 Because these reports mix routes and products, they do not tell us which effects come at which injected dose. Any prescriber should start with a history of heart symptoms, medicines, pregnancy and cancer.
What should you ask a prescriber about dose?
- What are the dose, the injection route and the schedule, and what published study or label supports each?
- What is the goal, and what result will tell us to stop?
- Which pharmacy compounds it, and how is it labeled and stored?
- Which symptoms mean stop and call, for example chest discomfort or a severe reaction?
- Have common causes of tiredness been checked first, such as sleep, thyroid, anemia and medicines?
Our look at whether NAD+ injections help energy covers the evidence on benefit, and whether NAD+ supplements are worth it covers the oral products. For how a different peptide's published doses compare with vendor claims, see sermorelin dosage in the studies. For tiredness itself, start with what happens to a man's body after 40.
Limits of the evidence
The trials above are small to modest in size, short, and about oral products, so they cannot validate an injection dose. The reviews describe the intravenous literature as preliminary. We searched PubMed and reviewed the abstracts listed here; we did not find a dose-finding trial of subcutaneous or intramuscular NAD+. If one is published, this page will be updated.
Questions
Is there a standard NAD+ injection dosage?
No. A 2026 review of intravenous NAD+ concluded that optimal dosing cannot currently be established, and compounded NAD+ injections have no FDA-approved label with a dose.
How much NAD+ precursor did trials use?
Oral trials used 250 mg per day of NMN, 2,000 mg per day of nicotinamide riboside in two trials, among others. These are swallowed doses and cannot be converted to injection doses.
Is a NAD+ dosage chart from a clinic reliable?
Not without a source. We found no controlled trial supporting a specific injection schedule, so ask which study a chart's numbers come from, in whom, and by which route.
Are compounded NAD+ injections FDA-approved?
No. The FDA states that compounded drugs are not FDA-approved and that it does not review their safety, effectiveness or quality before marketing.
What side effects are reported with NAD+?
The intravenous review lists nausea, cramping, flushing and chest discomfort. Oral-product trials reported muscle pain, fatigue, sleep disturbance and headache. Long-term safety data are lacking.
Also in this edition
Part of our guide: Aging Well: NAD+, Exercise and the Male Body After 40
Notes
- Alangari A, et al. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine. Front Aging. 2026. PubMed 42787547.
- Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022. PubMed 35927255.
- Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018. PubMed 29992272.
- Wu CY, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. 2025. PubMed 41357333.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- Gindri IM, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab. 2024. PubMed 37971292.
- Godic A, Townsend J. Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility. Acta Dermatovenerol Alp Pannonica Adriat. 2026. PubMed 41915584.